Psilocybin may be effective for treatment-resistant depression
Pharmaceutical journal/The pharmaceutical journal January 1, 2022 DOI: 10.1211/pj.2022.1.164911 via OpenAlex
Summary
AI-generated from the abstractA single 25mg dose of the psychedelic drug psilocybin, given alongside psychological support, may improve symptoms of treatment-resistant depression. This phase II trial, the largest of its kind to date, was conducted across 22 sites in 10 countries and published in the New England Journal of Medicine.
Study at a glance
| Characteristics | Phase II trial Peer reviewed |
|---|---|
| Population | People with treatment-resistant depression |
| Intervention | Psilocybin |
| Dose | 25 mg |
| Topics | Depression Psilocybin |
| Keywords | Depression economics Psychiatry Medicine |
| Key finding | A single 25mg dose of psilocybin with psychological support may improve symptoms of treatment-resistant depression. |
Abstract
The largest trial to date of the psychedelic drug psilocybin has shown that, alongside psychological support, a single 25mg dose may improve the symptoms of treatment-resistant depression. The phase II study, published in the New England Journal of Medicine on 3 November 2022, was conducted across 22 sites in 10 countries, including the UK, between […]